<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380636</url>
  </required_header>
  <id_info>
    <org_study_id>7339-012</org_study_id>
    <secondary_id>2019-003237-41</secondary_id>
    <secondary_id>MK-7339-012</secondary_id>
    <secondary_id>KEYLYNK-012</secondary_id>
    <secondary_id>205352</secondary_id>
    <nct_id>NCT04380636</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)</brief_title>
  <official_title>A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of pembrolizumab in&#xD;
      combination with concurrent chemoradiation therapy followed by either pembrolizumab with&#xD;
      olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation&#xD;
      therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced&#xD;
      NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label.&#xD;
      The primary hypotheses are:&#xD;
&#xD;
        1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with&#xD;
           olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with&#xD;
           respect to progression-free survival (PFS) and overall survival (OS)&#xD;
&#xD;
        2. pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is&#xD;
           superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS&#xD;
           and OS&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">July 6, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AE)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Rate of Study Intervention Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>An AE is defined as as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>ORR is defined as the percentage of participants who have achieved a Complete Response (CR) or a Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DOR is defined as the time from first documented evidence of Complete Response (CR) or a Partial Response (PR) until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Scale Score</measure>
    <time_frame>Baseline (at randomization) and at the end of study (approximately 72 months post randomization)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scale scores will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cough Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) Item 1 Score</measure>
    <time_frame>Baseline (at randomization) and at the end of study (approximately 72 months post randomization)</time_frame>
    <description>The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for cough (Item 1). For this item, individual responses to the question &quot;How much did you cough?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chest Pain Using the EORTC QLQ-LC13 Item 10 Score</measure>
    <time_frame>Baseline (at randomization) and at the end of study (approximately 72 months post randomization)</time_frame>
    <description>The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for chest pain (Item 10). For this item, individual responses to the question &quot;Have you had pain in your chest?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dyspnea Using the EORTC QLQ-C30 Item 8 Score</measure>
    <time_frame>Baseline (at randomization) and at the end of study (approximately 72 months post randomization)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients and includes a single-item scale score for dyspnea (Item 8). Participant responses to the question &quot;Were you short of breath? are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score</measure>
    <time_frame>Baseline (at randomization) and at the end of study (approximately 72 months post randomization)</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The physical functioning scale consists of participant responses to 5 questions regarding performance of daily activities [1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet]. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life. The change from baseline in the EORTC QLQ-C30 physical functioning scale score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in HRQoL Using the EORTC QLQ-C30 Items 29 and 30 Score</measure>
    <time_frame>Up to approximately 72 months post randomization</time_frame>
    <description>TTD is defined as the time to first onset of a ≥10-point decrease from baseline for EORTC QLQ-C30 Items 29 and 30 scale scores. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Cough Using the EORTC QLQ-LC13 Item 1 Score</measure>
    <time_frame>Up to approximately 72 months post randomization</time_frame>
    <description>TTD is defined as the time to first onset of a ≥10-point decrease from baseline for EORTC QLQ-LC13 Item 1 scale score. The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for cough (Item 1). For this item, individual responses to the question &quot;How much did you cough?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Chest Pain Using the EORTC QLQ-LC13 Item 10 Score</measure>
    <time_frame>Up to approximately 72 months post randomization</time_frame>
    <description>TTD is defined as the time to first onset of a ≥10-point decrease from baseline for EORTC QLQ-LC13 Item 10 scale score. The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for chest pain (Item 10). For this item, individual responses to the question &quot;Have you had pain in your chest?&quot; are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Dyspnea Using the EORTC QLQ-C30 Item 8 Score</measure>
    <time_frame>Up to approximately 72 months post randomization</time_frame>
    <description>TTD is defined as the time to first onset of a ≥10-point decrease from baseline for EORTC QLQ-C30 Item 8 scale score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients and includes a single-item scale score for dyspnea (Item 8). Participant responses to the question &quot;Were you short of breath? are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score</measure>
    <time_frame>Up to approximately 72 months post randomization</time_frame>
    <description>TTD is defined as the time to first onset of a ≥10-point decrease from baseline for EORTC QLQ-C30 Items 1-5 scale scores. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The physical functioning scale consists of participant responses to 5 questions regarding performance of daily activities [1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet]. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">870</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenous (IV) infusion</description>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <other_name>LYNPARZA®</other_name>
    <other_name>MK-7339</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for olaparib</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>VEPESID®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>PARAPLATIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>PLATINOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>TAXOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
    <other_name>ALIMTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic Radiotherapy</intervention_name>
    <description>external beam radiation</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib</arm_group_label>
    <arm_group_label>pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiation→durvalumab</arm_group_label>
    <other_name>IMFINZI®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC&#xD;
&#xD;
          -  Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8&#xD;
&#xD;
          -  Is unable to undergo surgery with curative intent for Stage III NSCLC&#xD;
&#xD;
          -  Has no evidence of metastatic disease indicating Stage IV NSCLC&#xD;
&#xD;
          -  Has measurable disease as defined by RECIST 1.1&#xD;
&#xD;
          -  Has not received prior treatment (chemotherapy, targeted therapy or radiotherapy) for&#xD;
             Stage III NSCLC; participants who have received neoadjuvant and/or adjuvant therapy&#xD;
             for early stage disease are not eligible&#xD;
&#xD;
          -  Has provided a tumor tissue sample (tissue biopsy [core, incisional, or excisional])&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed&#xD;
             within 7 days prior to the first administration of study intervention&#xD;
&#xD;
          -  Has a life expectancy of at least 6 months&#xD;
&#xD;
          -  A male participant must agree to use contraception and refrain from donating sperm&#xD;
             during the intervention period and for at least the time needed to eliminate each&#xD;
             study intervention after the last dose of study intervention. The length of time&#xD;
             required to continue contraception for each study intervention is as follows: Olaparib&#xD;
             and platinum doublet: 90 days&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and agrees to use contraception and refrain from donating eggs (ova,&#xD;
             oocytes) to others or freeze/store for her own use for the purpose of reproduction&#xD;
             during the treatment period and for at least the time needed to eliminate each study&#xD;
             intervention after the last dose of study intervention. The length of time required to&#xD;
             continue contraception for each study intervention is as follows: Pembrolizumab: 120&#xD;
             days Olaparib and platinum doublet: 180 days&#xD;
&#xD;
          -  Has a negative highly sensitive pregnancy test ([urine or serum] as required by local&#xD;
             regulations) within 24 hours for urine or within 72 hours for serum before the first&#xD;
             dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an&#xD;
             ambiguous result), a serum pregnancy test is required. In such cases, the participant&#xD;
             must be excluded from participation if the serum pregnancy result is positive.&#xD;
&#xD;
          -  Has had her medical history, menstrual history, and recent sexual activity reviewed by&#xD;
             the investigator to decrease the risk for inclusion of a woman with an early&#xD;
             undetected pregnancy.&#xD;
&#xD;
          -  Has adequate pulmonary function tests&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  Has provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has small cell lung cancer or a mixed tumor with presence of small cell elements&#xD;
&#xD;
          -  Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features&#xD;
             suggestive of MDS/AML&#xD;
&#xD;
          -  Has had documented weight loss &gt;10% (from baseline) in the preceding 3 months&#xD;
&#xD;
          -  Has received prior radiotherapy to the thorax, including radiotherapy to the&#xD;
             esophagus, mediastinum, or for breast cancer&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death 1 (ant-PD-1),&#xD;
             anti-programmed cell death ligand 1 (anti-PD-L1), or anti- programmed cell death&#xD;
             ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Has received prior therapy with olaparib or with any other polyadenosine&#xD;
             5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor&#xD;
&#xD;
          -  Has had major surgery &lt;4 weeks prior to the first dose of study treatment (except for&#xD;
             placement of vascular access)&#xD;
&#xD;
          -  Is expected to require any other form of antineoplastic therapy, while on study&#xD;
&#xD;
          -  Has received a live or live attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention; administration of killed vaccines is allowed&#xD;
&#xD;
          -  Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor&#xD;
             [GCSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant&#xD;
             erythropoietin) within 28 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin,&#xD;
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or&#xD;
             moderate (e.g. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be&#xD;
             discontinued for the duration of the study&#xD;
&#xD;
          -  Is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin,&#xD;
             protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir,&#xD;
             nelfinavir, boceprevir, telaprevir) or moderate (eg. ciprofloxacin, erythromycin,&#xD;
             diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot&#xD;
             be discontinued for the duration of the study&#xD;
&#xD;
          -  Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs),&#xD;
             other than an aspirin dose ≤1.3 grams per day, for at least 2 days before, during, and&#xD;
             for at least 2 days after administration of pemetrexed&#xD;
&#xD;
          -  Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone during&#xD;
             administration of pemetrexed&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  The presence of uncontrolled, potentially reversible cardiac conditions, as judged by&#xD;
             the investigator or has congenital long QT syndrome&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 5 years with the exception of basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ&#xD;
             (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially&#xD;
             curative therapy&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to study intervention and/or any of its&#xD;
             excipients&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has active tuberculosis (TB; Mycobacterium tuberculosis) and is receiving treatment&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the participant's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the participant to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Is considered a poor medical risk due to a serious, uncontrolled medical disorder or&#xD;
             nonmalignant systemic disease in the opinion of the treating investigator&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study&#xD;
&#xD;
          -  Is unable to swallow orally administered medication or has a gastrointestinal disorder&#xD;
             affecting absorption&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama, Mitchell Cancer Institute ( Site 0003)</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>251-665-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Bernards Medical Center ( Site 0089)</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>870-207-8177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare-Oncology ( Site 0088)</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-446-7900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center ( Site 0006)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806-1737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-933-7866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Santa Monica ( Site 0013)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-829-5471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare ( Site 0011)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-543-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Physician Network / Cancer Center ( Site 0093)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-750-3376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital-Memorial Cancer Institute ( Site 0095)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System ( Site 0024)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-575-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Center ( Site 0022)</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>386-774-1223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health, UF Health Cancer Center Inc ( Site 0092)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>321-841-1869</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology ( Site 0094)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>260-436-0800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center ( Site 0032)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>833-724-8326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health ( Site 0031)</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-528-1580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky ( Site 0096)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-257-3379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Brownsboro Hospital-Norton Cancer Institute - Brownsboro ( Site 0035)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-629-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pikeville Medical Center ( Site 0036)</name>
      <address>
        <city>Pikeville</city>
        <state>Kentucky</state>
        <zip>41501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>606-218-2212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0038)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-1223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital ( Site 0045)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-2635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA St. Louis Health Care System ( Site 0047)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-289-7690</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Siteman Cancer Center ( Site 0046)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-7222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Health St. Francis ( Site 0053)</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>308-398-6518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey ( Site 0054)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-235-2465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital ( Site 0056)</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>201-447-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center ( Site 0083)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-405-8477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian ( Site 0081)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-384-8823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center ( Site 0050)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-681-5698</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Hematology-Oncology Associates ( Site 0080)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-277-8800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at The Christ Hospital ( Site 0060)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0063)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-369-2427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic ( Site 0066)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-328-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0075)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-277-3101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest ( Site 0074)</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-228-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre ( Site 0100)</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9024738317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0102)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5148908000 ext 24348</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0108)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+15143453511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0110)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185254444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Investigación del Cáncer James Lind ( Site 0202)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56974316500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OrlandiOncologia ( Site 0201)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500713</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992214787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradfordhill ( Site 0200)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998744662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 0203)</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992369820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Antofagasta ( Site 0204)</name>
      <address>
        <city>Antofagasta</city>
        <zip>1240000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994198125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital ( Site 3201)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861069156114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences ( Site 3213)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613520445135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 3212)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8601088196984</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 3224)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8601088196479</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daping Hospital,Third Military Medical University ( Site 3235)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02368811229</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital ( Site 3226)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613906900190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University ( Site 3219)</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0592-2137572</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital ( Site 3216)</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613823394076</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3200)</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518116</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0755-66619602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital ( Site 3205)</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>865512922342</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital ( Site 3222)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 13871244098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 3218)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613886048178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 3238)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0731-88651900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University ( Site 3637)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>073184328888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central-South University ( Site 3227)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0731-85295888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 3225)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0731-88651900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital ( Site 3234)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613913909043</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University ( Site 3206)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613767120022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital ( Site 3230)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86043185879120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital ( Site 3207)</name>
      <address>
        <city>Shangai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 13651635103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 3220)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>13601783113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital ( Site 3203)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-65115006(2131)</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University ( Site 3202)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>510115</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02885422114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 3204)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613102258620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3232)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613957162839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav ( Site 2206)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420543132450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava ( Site 2201)</name>
      <address>
        <city>Ostrava</city>
        <state>Ostrava Mesto</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420597372124</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady ( Site 2200)</name>
      <address>
        <city>Prague</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420724318145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole ( Site 2210)</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavni Mesto</state>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224434700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Plesi s.r.o. ( Site 2202)</name>
      <address>
        <city>Nova Ves pod Plesi</city>
        <state>Pribram</state>
        <zip>262 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420318541416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec, a.s. ( Site 2209)</name>
      <address>
        <city>Liberec</city>
        <zip>468 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420606540548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze ( Site 2208)</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224962219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce ( Site 2205)</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420266082267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation ( Site 1601)</name>
      <address>
        <city>Tallin</city>
        <state>Harjumaa</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>372171792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital ( Site 1600)</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3725513443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Clairval ( Site 0802)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0033496196230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Brest - Hopital Morvan ( Site 0806)</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois ( Site 0811)</name>
      <address>
        <city>Epagny Metz Tessy</city>
        <state>Haute-Savoie</state>
        <zip>74730</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33450636603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Teissier Groupe ( Site 0808)</name>
      <address>
        <city>Valenciennes</city>
        <state>Nord</state>
        <zip>59304</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3327142434</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 0803)</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33148955032</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe-Service de pneumologie ( Site 0816)</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33360125235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.I.A. Sainte-Anne ( Site 0815)</name>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33483162916</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendee ( Site 0807)</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>Vendee</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33251446161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden ( Site 0908)</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4957179054253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GEHO Muenster ( Site 0910)</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4902516200817</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf GmbH ( Site 0901)</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+491026012101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH ( Site 0905)</name>
      <address>
        <city>Bad Berka</city>
        <state>Thuringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4936458543122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena ( Site 0911)</name>
      <address>
        <city>Jena</city>
        <state>Thuringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4936419396670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 0900)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930450553004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Marienkrankenhaus gGmbH ( Site 0902)</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494025462508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2302)</name>
      <address>
        <city>Kecskemét</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>003676516719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2303)</name>
      <address>
        <city>Gyula</city>
        <state>Bekes</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0036704533531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 2306)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>96507900 ext4141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi Pulmonologiai Intezet ( Site 2305)</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0036703288101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Umberto I- Torrette ( Site 1009)</name>
      <address>
        <city>Torrette</city>
        <state>Ancona</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390715964169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi ( Site 1001)</name>
      <address>
        <city>Florence</city>
        <state>Firenze</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390557947192</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Research Hospital ( Site 1000)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi ( Site 1003)</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390832661962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1008)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223903813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena ( Site 1007)</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390594223864</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli ( Site 1002)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+00390630156318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Santa Maria della Misericordia di Udine ( Site 1004)</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390432554550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe Minimally Invasive Cancer Center ( Site 3100)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-78-304-4100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center ( Site 3101)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-520-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital ( Site 3103)</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-804-0101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical and Pharmaceutical University Hospital ( Site 3110)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-683-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center ( Site 3104)</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-541-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital ( Site 3109)</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-25-266-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 3106)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6945-1181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital ( Site 3111)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital ( Site 3108)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3823-2101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 3107)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3520-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital ( Site 3105)</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3784-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital ( Site 2802)</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungbuk</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82432696015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 2800)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319200406</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent s Hospital ( Site 2805)</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Kyonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82318818901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2801)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877041</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital ( Site 2803)</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82312195142</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital ( Site 2804)</name>
      <address>
        <city>Jinju-si</city>
        <state>Kyongsangnam-do</state>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82557508066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital ( Site 2807)</name>
      <address>
        <city>Daegu</city>
        <state>Taegu-Kwangyokshi</state>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82532587716</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital ( Site 2806)</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220011859</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2808)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222280870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital ( Site 1501)</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37129410710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital ( Site 1500)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37129455458</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>523315145351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot; ( Site 0508)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64400</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8183338111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLIMERS Clinical Medical Research ( Site 0506)</name>
      <address>
        <city>Orizaba</city>
        <state>Veracruz</state>
        <zip>94300</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+522727282900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia ( Site 0502)</name>
      <address>
        <city>Tlalpan</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525513150894</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF ( Site 1106)</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4767960000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF Drammen Sykehus ( Site 1101)</name>
      <address>
        <city>Drammen</city>
        <state>Buskerud</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4732862464</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Oestfold ( Site 1107)</name>
      <address>
        <city>Gralum</city>
        <state>Ostfold</state>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4769860000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger HF Stavanger Universitetssjukehus ( Site 1103)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4751518000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF. Ulleval ( Site 1100)</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4722934809</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)</name>
      <address>
        <city>Arequipa</city>
        <state>Ariqipa</state>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5154380550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncosalud ( Site 0605)</name>
      <address>
        <city>Lima</city>
        <state>Muni Metro De Lima</state>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5112053500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0606)</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51997881134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica San Gabriel ( Site 0601)</name>
      <address>
        <city>Lima</city>
        <zip>15088</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51998718091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia ( Site 0602)</name>
      <address>
        <city>Lima</city>
        <zip>15102</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51 942 499 515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400)</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48224800800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2401)</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48895398428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Bucuresti ( Site 2508)</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40216012610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2506)</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40745976913</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Radiotherapy Center Cluj S.R.L ( Site 2503)</name>
      <address>
        <city>Comuna Floresti</city>
        <state>Cluj</state>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40742206212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinica Oncomed SRL ( Site 2504)</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40723401453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C.Focus Lab Plus S.R.L ( Site 2500)</name>
      <address>
        <city>Bucuresti</city>
        <zip>022548</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40721298677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501)</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40 724877013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi ( Site 2505)</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40374278811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79127949047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1903)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7(495)9454941</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod Region Oncology Dispensary ( Site 1914)</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107959868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1905)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78125968538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical institute named after Berezin Sergey ( Site 1906)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Hospital ( Site 1909)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79222022945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1911)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7(843)2022340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1910)</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+89106654167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1202)</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 1200)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.R.U Málaga - Hospital General ( Site 1206)</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 95 129 14 25</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.U. Vall de Hebron ( Site 1201)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona ( Site 1204)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena ( Site 1205)</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955926578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe ( Site 1203)</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 96 141 19 69</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University ( Site 3003)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6622564533</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital. ( Site 3000)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6624197388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University Maharaj Nakorn Chiang Mai Hospital ( Site 3001)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6653938887</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital. Khon Kaen University ( Site 3002)</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6643204432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Ankara Hastanesi ( Site 2006)</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905067521275</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi ( Site 2002)</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905555306271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 2000)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medipol Universite Hastanesi ( Site 2003)</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325280486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2001)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905063509061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty ( Site 2005)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322202675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0800331496</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SOGrigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine-Clinical oncology and hematology (</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380577255058</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC Ukrainian Center of Tomotherapy ( Site 2105)</name>
      <address>
        <city>Kropyvnytskyi</city>
        <state>Kirovohradska Oblast</state>
        <zip>25011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380979428527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104)</name>
      <address>
        <city>Kapitanivka Village</city>
        <state>Kyivska Oblast</state>
        <zip>08111</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380992163443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of the MoH of Ukraine ( Site 2101)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509095151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Center ( Site 2100)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503818536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Verum ( Site 2106)</name>
      <address>
        <city>Kyiv</city>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380997799214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital NHS Foundation Trust ( Site 1403)</name>
      <address>
        <city>London</city>
        <state>Essex</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442034474698</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust ( Site 1410)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+02071882006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Sutton) ( Site 1407)</name>
      <address>
        <city>London</city>
        <state>Surrey</state>
        <zip>SM3 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442086426011</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death Receptor 1 (PD-1, PD1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2)</keyword>
  <keyword>polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

